Outpatient electrical cardioversion of atrial fibrillation: Efficacy, safety and patients' quality of life

A dedicated cardioversion unit for the treatment of atrial fibrillation. Reducing costs by optimizing processes

BACKGROUND

Atrial fibrillation (AF) is the most frequent arrhythmia seen in man. Many patients are admitted to the hospital to undergo transesophageal echocardiography (TEE) for thrombus exclusion and subsequent electrical cardioversion (ECV) under deep sedation to restore sinus rhythm. The present study investigated prospectively how workflow optimization can contribute to reducing time and costs in AF patients scheduled for ECV in an outpatient setting.

METHODS

A cardioversion unit (CU) was established and equipped to perform all ECV-associated procedures. Between November 2007 and January 2009, ECV was performed in 115 patients in an outpatient setting. Three different settings were tested for ECV: (1) usual care (n = 19): preparation/follow-up in the outpatient clinic, blood testing in the central hospital laboratory (CHL), TEE in the echocardiography laboratory, and ECV in the intensive care unit; (2) optimized process 1 (n = 41): preparation/follow-up, TEE + ECV during one sedation in the CU, blood testing in the CHL; (3) optimized process 2 (n = 55): preparation/follow-up, TEE + ECV and point of care (POC) blood testing in the CU. All procedure-related costs were listed and classified according to material, human resources, and infrastructure.

RESULTS

From setting 1 to 3, there was a significant decrease in procedural time from 480 ± 105 min to 205 ± 85 min (p < 0.001). Likewise, ECV-associated costs could be reduced from 683 ± 104 <euro> to 299 ± 63 <euro> (p < 0.001).

CONCLUSION

Establishing a CU for AF enables a more than 50% reduction in procedural time and costs. A combination of TEE and ECV in one sedation and POC testing in the CU were the major contributors to this time and cost reduction.

General anaesthesia for external electrical cardioversion of atrial fibrillation: experience of an exclusively cardiological procedural management

AIMS

External electrical cardioversion (EC) usually requires brief general anaesthesia involving anaesthetists. The aim of this study was to evaluate the feasibility and safety of inducing anaesthesia for EC of atrial fibrillation (AF) exclusively by the cardiologic team with anaesthetists on-hand.

METHODS AND RESULTS

A retrospective analysis of 624 elective EC, over a 6-year period, was made. No patients were excluded due to the severity of pathology or comorbidities. The protocol of the intravenous anaesthesia was 5 mg bolus of midazolam and subsequent increasing doses of propofol starting from 20 mg to achieve the desired sedation level. After delivering DC shock, a direct observation period followed in order to assess the post-sedation recovery and to detect the procedure-related complications. Electrical cardioversion was effective in 98.9% of the cases. General anaesthesia was effective in 100% of cases with a dosage of propofol, ranging between 20 mg to a maximum of 80 mg, after 5 mg of midazolam was administered. All patients generally showed a fast recovery waking up in a few minutes. The anaesthesiology team was never called for assistance. All the procedures were carried out by the cardiologic team as planned. No thrombo-embolic and allergic complications were observed. Arrhythmic complications were uncommon and essentially bradyarrhythmias.

CONCLUSION

A general anaesthesia for outpatient EC of AF can be safely handled by a cardiologist having adequate experience with anaesthetical agents. Moreover, the association of midazolam and a very small dosage of propofol, given their synergic action, is effective and safe in inducing anaesthesia. Arrhythmic complications are rare and limited to bradyarrhythmias.

Responsiveness of AF6, a new, short, validated, atrial fibrillation-specific questionnaire--symptomatic benefit of direct current cardioversion

Objectives

To measure the effects on symptoms of electrical cardioversion (DC) in patients with atrial fibrillation (AF) by means of a new, short, validated, AF-specific questionnaire, the AF6.

Methods

One hundred eleven patients (67 ± 12 years, 89 men) were screened before and 12 ± 3 days after DC using AF6, covering ‘breathing difficulties at rest’, ‘breathing difficulties on exertion’, ‘limitations in day-to-day life due to atrial fibrillation’, ‘feeling of discomfort due to atrial fibrillation’, ‘tiredness due to atrial fibrillation’, and ‘worry/anxiety due to atrial fibrillation’. A single global score was calculated. The Toronto AF Symptoms and Severity Check List (AFSS) and the generic SF-36 were also administered. Patients in sinus rhythm at 12 ± 3 days (n = 56) were defined as responders and patients in AF (n = 55) as non-responders.

Results

The mean single global score decreased in all patients (18 ± 12.4 to 13 ± 11.6, p < 0.0001) and in responders (22 ± 14 vs. 12 ± 12, p < 0.01) but not in non-responders (14 ± 9 vs. 14 ± 11, N.S). The AFSS frequency scores decreased from 14.5 ± 7.7 to 9.5 ± 7.8 in responders, p = 0.001, but not in non-responders. There was a strong correlation between changes in the AF6 and the SF-36 regarding four of the six items. Effect sizes of AF6 ranged from 0 to 0.52 in all patients, in responders from 0.10 to 0.85 and in non-responders from −0.23 to 0.34, the highest figures consistently referring to ‘tiredness due to atrial fibrillation’.

Conclusions

The symptom scores measured by AF6 decreased significantly, especially in responders. AF6 demonstrated adequate responsiveness to change, and effect sizes were mostly moderate, in responders moderate to high.

Outpatient electrical cardioversion of atrial fibrillation: 8 years' experience. Analysis of shock-related arrhythmias

BACKGROUND

Outpatient electrical cardioversion (EC) of atrial fibrillation is currently the standard of care. Shock-related arrhythmias may be particularly deleterious in this setting. Preoperative identification of high-risk patients may be very useful.

METHODS

A retrospective analysis was made of 543 consecutive elective EC procedures in 457 outpatients over an 8-year period in a university cardiological institute. The protocol included adequate anticoagulation, intravenous anesthesia, direct current shock, and a direct observation after a shock to detect procedure-related complications. No patients were excluded due to severity of pathology or comorbidities. Clinical characteristics, energy delivered, medications, arrhythmic phenomena, and predictors of success and complications were analyzed.

RESULTS

Of 543 ECs performed, 88.2% restored sinus rhythm, which persisted at discharge in 83.2%. No anesthesia-related complications were detected. No thromboembolic complications were detected. Use of a biphasic cardioverter was the only predictor of success (P = 0.0001). The bradyarrhythmic complication rate was 1.5%. No ventricular arrhythmic events were detected. Atrial flutter was present in five of eight patients who developed complications versus 44 of 535 patients who had no complications (P < 0.0005), and prosthetic heart valves in four of eight complicated versus 40 of 535 uncomplicated cases (P = 0.0044). The combination of atrial flutter and prosthetic heart valve was found in four of eight complicated versus 11 of 535 uncomplicated cases (P < 0.0005).

CONCLUSION

Shock-related arrhythmias are essentially bradyarrhythmias. Atrial flutter and previous cardiac surgery identify a subgroup of patients at high risk of postshock bradyarrhythmic complications.

Anatomical remodeling of left atria in subjects with chronic and paroxysmal atrial fibrillation evaluated by multislice computed tomography

PURPOSE

We used ECG-gated enhance multislice computed tomography (MSCT) to evaluate and compare anatomical change to left atria (LA) including left atrial appendage (LAA) in subjects with chronic and paroxysmal atrial fibrillation (CAF and PAF, respectively).

MATERIALS AND METHODS

Retrospective ECG-gated MSCT (Light Speed Ultra 16, General Electric) was performed in 16 subjects with CAF (10 male, median age 68/period of CAF 6 years, 3 severe or moderate mitral stenosis (MS), 3 mitral regurgitation (MR)) and 17 with PAF (11 male, median age 62/period of PAF 3 years, one MS, one MR) 30 s and 8 min after injection of contrast. We evaluated: qualified observed morphology of pectinate muscles (PM) in LAA (well/poorly/non-developed); absolute thickness of LA anterior wall; presence of abnormal late enhancement (LE) of LA wall suggesting fibrotic changes; defect of contrast in LAA only in early phase and LAA enlargement; comparison of LA diameter evaluated by 4-chamber view obtained by transthoracic echocardiogram.

RESULTS

CAF group: well-developed PM (19% subjects), poor PM (43%), no PM (38%). PAF group: well-developed PM (41%), poor PM (47%), no PM (12%). Incidences of well- and non-developed PM were significantly less and more in CAF group, respectively. CAF subjects with no PM had longer periods of CAF and larger LA diameter than those with developed PM (p<0.01). By contrast, there was no relation between PM morphology and PAF periods or LA diameter. Incidence and mean thickness of abnormal LE of LA wall were similar in both groups (2.6 mm): 25% (CAF); 24% (PAF). There was a negative correlation in the CAF group between thickness of LA wall and LA diameter (R2=0.19), but not in the PAF group. Contrast defect in LAA only in early phase and enlargement of LAA were observed in 56%, 88% (CAF) and 24%, 41% (PAF); ratios were significantly higher in CAF group (p<0.01).

CONCLUSIONS

There were anatomical differences between CAF and PAF groups in MSCT. In CAF group, depending on the period of CAF or degree of LA diameter enlargement, anatomical remodeling (e.g. recession of PM, thinning of LA wall, enlargement of LAA) may appear, which may cause blood flow stagnation, seen as contrast defect in LAA in early phase.